Abstract: Provided herein are timosaponin compounds of Formula I, II, III, I?, II? and III?, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are uses of said timosaponin compounds for preparing medicament for the treatment of diseases associated with beta-amyloid in hosts or subjects in need thereof.

Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein each of the variables listed above are as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein L and Ring A are as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides methods of making a compound of formula II: or a pharmaceutically acceptable salt thereof, wherein R1, R2, and L are as defined and described herein.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein Rx is as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein Rx is as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R1 and R5 are as defined and described herein, compositions thereof, and methods of using the same.

Abstract: The present invention relates to a compound of following formula (I): or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for treating a proliferative disease such as cancer.

Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Abstract: This invention relates to certain sugar esters of phytosterols of formula (I).

Abstract: The invention relates to novel betulinic acid derivatives of formula (I), wherein R is C(?CH2) CH3 or CH(CH3)2; R2 together with the adjacent carbonyl group forms a carboxylic acid, carboxylic acid ester or amide or substituted amide; R3 or R4 are hydrogen or aryl with the proviso that both are not independently hydrogen or alkyl or R3 and R4 are combined together to form an aryl ring optionally substituted with a group X, wherein X is selected from halogen, alkyl, cyano, nitro, alkoxy, amino or substituted amine; Y is N or O; and R1 is zero when Y is O, and R1 is hydrogen, alkyl or aryl alkyl when Y is N, useful for inhibition of tumor cancer cells.

Abstract: The present invention relates to useful diterpenes and pharmaceutical compositions containing them of the formula: for use in the treatment of cardiovascular and inflammatory diseases and for cancers susceptible to an NF-?B inhibitor and an endothelin receptor inhibitor. The present invention also relates to compounds and methods useful to inhibit cell proliferation and for the induction of apoptosis.

Abstract: Disclosed are compounds that exhibit high transport across the intestinal wall of an animal. The compounds may optionally be linked to drugs that are poorly absorbed or poorly transported across the intestinal wall after oral administration to provide for enhanced therapeutic, and optionally prolonged therapeutic, systemic blood concentrations of the drugs upon oral administration of the drug-compound conjugate. Also disclosed are pharmaceutical compositions containing and methods of using such compounds.

Abstract: Described herein is the isomerisation process of 6&bgr;-fluorosteroids into the corresponding pharmacologically active 6&agr;-fluoro derivatives, comprising the reaction of 6&bgr;-fluorosteroids, or 6&agr;/6&bgr; isomeric mixtures, with an organic base containing a diazoimino group in a suitable organic solvent.

Abstract: 5'-Alkylsulfonylsteroido[3,2-b]furans, for example 5'-methylsulfonyl-5.alpha.-pregn-2-en-20-yno[3,2-b]furan-17.beta.-ol having the structural formula, ##STR1## which are useful as antiandrogenic agents, and processes for preparation, method of use and compositions thereof are disclosed.